{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Exploring the Cardiovascular Continuum: Insights from Practicing Cardiologists (CARDIO-INSIGHTS)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. In your professional experience, which of the following conditions do you consider to be most strongly associated with endothelial dysfunction in patients with cardiovascular diseases? (Tick multiple-options, if applicable) *

  2. From your observations and practice, which risk factor do you believe contributes most significantly to the development of endothelial dysfunction among your patients? (Tick multiple-options, if applicable) *

  3. How strongly do you agree with the statement: "Addressing endothelial dysfunction is crucial in the management of cardiovascular diseases"? *

  4. Based on your clinical experience, which pharmacological treatment do you find to be the most effective in improving endothelial function in patients? *

  5. To what extent do you agree with the statement: "Regular exercise is the most impactful lifestyle modification for improving endothelial function"? *

  6. Which diagnostic test do you consider to be the most reliable for assessing the presence of atherosclerotic plaques in patients? *

  7. How frequently do you screen your patients who have cardiovascular risk factors for dyslipidemia? *

  8. How strongly do you agree with the following statement: "LDL-C is the most important lipid parameter to target in patients with atherosclerosis"? *

  9. In your opinion, which of the following is the most significant risk factor for developing atherosclerosis in your patient population? *

  10. How strongly do you agree with the statement: "Inflammation plays a critical role in the pathogenesis of atherosclerosis"? *

  11. In your clinical practice, which lipid parameter do you find the most challenging to manage effectively in your patients? *

  12. How strongly do you agree with the following statement: "Statins are the first-line therapy for managing dyslipidemia in patients with atherosclerosis"? *

  13. PCSK9 inhibitors are considered a valuable addition to statin therapy for patients presenting with very high LDL-C levels. To what extent do you agree with this statement? *

  14. In your opinion, what is the main barrier to achieving optimal lipid control in your patients? *

  15. How often do you encounter patients who are intolerant to statins in your practice? *

  16. Emerging therapies such as RNA-based treatments (e.g., inclisiran) have the potential to revolutionize the management of dyslipidemia. How strongly do you agree with this statement? *

  17. To what extent do you believe that the use of advanced imaging techniques will significantly improve the early detection of atherosclerosis? *

  18. How strongly do you agree with the following statement: "Patient education on lifestyle changes is as crucial as pharmacotherapy in managing dyslipidemia"? *

  19. How often do you discuss dietary modifications with your patients as part of managing dyslipidemia? *

  20. Do you think that regular follow-up and monitoring improve patient outcomes in the management of dyslipidemia? *

  21. Which dietary approach do you find to be the most effective for patients with dyslipidemia? *

  22. How strongly do you agree with the statement: "Implementing a multidisciplinary team approach significantly benefits patients with atherosclerosis and dyslipidemia"? *

  23. Which diagnostic tool do you consider to be the most reliable for diagnosing coronary artery disease (CAD)? *

  24. How often do you use coronary calcium scoring in your practice to assess the risk of CAD? *

  25. How strongly do you agree with the statement: "The use of high-sensitivity C-reactive protein (hs-CRP) is important in assessing inflammation in CAD patients"? *

  26. Statins are the first-line therapy for managing dyslipidemia in CAD patients. To what extent do you agree with this statement? *

  27. How frequently do you recommend the use of PCSK9 inhibitors for patients with CAD who are not achieving LDL-C targets with statins alone? *

  28. Which antiplatelet therapy do you prefer for secondary prevention in CAD patients? *

  29. How strongly do you agree with the statement: "Coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention (PCI) for patients with complex multi- vessel disease"? *

  30. How often do you perform fractional flow reserve (FFR) assessments during coronary interventions? *

  31. In your opinion, how viable is percutaneous coronary intervention (PCI) as a treatment option for patients with chronic total occlusions (CTO)? *

  32. How essential do you believe cardiac rehabilitation is for improving outcomes in coronary artery disease (CAD) patients post-intervention? *

  33. How frequently do you monitor your CAD patients for medication adherence? *

  34. In your practice, what do you consider the most significant barrier to optimal management of CAD? *

  35. How often do you discuss dietary modifications with your CAD patients as part of their management plan? *

  36. In your clinical experience, what percentage of CAD patients successfully quit smoking after diagnosis? and how does this impact their disease management? *

  37. Considering the various factors that contribute to secondary prevention in CAD patients, how would you rank the importance of regular physical activity? *

  38. Which of the following is a key feature of myocardial remodeling in heart failure? (Tick multiple-options, if applicable) *

  39. In your clinical experience, what is the primary cause of myocardial fibrosis in heart failure? *

  40. What role does neurohormonal activation play in myocardial remodeling? *

  41. Which imaging modality do you find most useful in assessing left ventricular remodeling? *

  42. How does Endothelin-1 contribute to myocardial remodeling? *

  43. Which medication class is typically NOT used to manage heart failure with myocardial remodeling? *

  44. How strongly do you agree with the statement: "Early intervention in myocardial remodeling can improve long-term outcomes in heart failure patients"? *

  45. Which therapeutic approach is directly aimed at reducing myocardial fibrosis? *

  46. Which procedure do you find most effective for assessing myocardial viability in heart failure? *

  47. How strongly do you agree with the statement: "Angiotensin receptor-neprilysin inhibitors (ARNIs) have a significant impact on reducing myocardial remodeling"? *

  48. What is a common clinical consequence of progressive myocardial remodeling in heart failure? *

  49. How essential do you believe biomarkers such as NT-proBNP are in monitoring the progression of heart failure? *

  50. Which patient characteristic do you find most predictive of adverse remodeling post- myocardial infarction? *

  51. How strongly do you agree with the statement: "Cardiac resynchronization therapy (CRT) can reverse myocardial remodeling in certain heart failure patients"? *

  52. What is the effect of prolonged untreated hypertension on myocardial remodeling? *

  53. Which of the following is a direct effect of aldosterone on myocardial tissue? *

  54. How strongly do you agree with the statement: "Advanced imaging techniques such as strain echocardiography are crucial in the early detection of myocardial remodeling"? *

  55. Which factor do you consider most critical in determining the reversibility of myocardial remodeling? *

  56. To what extent do you agree with the statement: "Lifestyle modifications have little impact on the progression of myocardial remodeling"? *

  57. What do you consider the primary goal of managing myocardial remodeling in heart failure? (Tick multiple-options, if applicable) *

  58. What is your preferred initial diagnostic tool for hypertension? (Tick multiple-options, if applicable) *

  59. Which of the following do you consider a common secondary cause of hypertension? (Tick multiple-options, if applicable)*

  60. To what extent do you agree with the statement: "Routine screening for hypertension should begin at age 18"? *

  61. According to the latest ACC/AHA guidelines (2023), which blood pressure measurement indicates stage 1 hypertension? *

  62. How strongly do you agree with the statement: "Ambulatory blood pressure monitoring is the gold standard for diagnosing white coat hypertension"? *

  63. What do you consider the first-line treatment for primary hypertension? *

  64. Which medication class do you prefer for treating hypertension in patients with chronic kidney disease? *

  65. How strongly do you agree with the statement: "Combination therapy is often required to achieve target blood pressure in patients with stage 2 hypertension"? *

  66. Which organ do you consider most commonly affected by hypertensive damage? *

  67. To what extent do you agree with the statement: "Hypertension is a significant risk factor for developing atrial fibrillation"? *

  68. How strongly do you agree with the statement: "Hypertension management should be individualized based on the patient's comorbid conditions"?*

  69. Which antihypertensive medication do you find most appropriate for a patient with hypertension and diabetes mellitus? *

  70. Which lifestyle modification do you believe has the greatest impact on lowering blood pressure? *

  71. To what extent do you agree with the statement: "Patient adherence to antihypertensive therapy is a major challenge in hypertension management"? *

  72. What do you recommend as the frequency for monitoring blood pressure in patients with controlled hypertension? *

  73. Which diagnostic tool do you most commonly use first in the evaluation of a suspected acute ischemic stroke? *

  74. How strongly do you agree with the statement: "Thrombolytic therapy should be administered within 4.5 hours of stroke onset for optimal outcomes"? *

  75. Which antiplatelet therapy do you most commonly recommend for the secondary prevention of ischemic stroke? *